This website is intended for Ireland Healthcare Professionals only. Not a Healthcare Professional in Ireland? Click here

Ms A

  • Hot flushes, night sweats
  • Breakthrough bleeding on HRT

Age: 55

Ms A

Menopause symptoms at initiation

  • Had been taking HRT but experienced unscheduled bleeding
  • Stopped HRT and hot flushes and night sweats had returned
  • Hot flushes day and night necessitates a fan. Up to 20 per 24 hours.
  • Sleep affected
  • Onset of hot flushes & night sweats: 4 months ago

Medical history and comorbidities

  • Postnatal depression
  • Anxiety
  • Abdominoplasty
  • Hypertension
  • Vestibular balance disorder
  • Hay fever

Basis for treatment decision

  • Non-hormonal options were discussed e.g. venlafaxine* and Oxybutynin** but explained that not all are licenced
  • Felt that fezolinetant offered a licensed option with a favourable side effect profile

Response to treatment with VEOZA

  • Frequency of hot flushes reduced
  • Patient’s sleep improved
  • Improved quality of life
  • Severity of VMS changed from severe at baseline to mild at month 3

VMS at 3 months of VEOZA Treatment

  • 1 hot flush in 24 hours

Adverse Events

  • None reported

Liver Function testing

Liver function tests performed and all results normal. Will continue with annual liver function testing***.

 

Please see https://www.veoza.ie/dosing for requirements for liver function testing with VEOZA

Clinician’s comments

“Patient is now sleeping well as the VMS have no impact on her life. She notices she gets a small rise in temperature early evening. Has given her quality of life back without the side effect of bleeding.”

Fast relief of hot flushes & night sweats.

Fast relief of hot flushes & night sweats. 1 dose a day, no titration.1,2

*Venlafaxine is not licensed for the treatment of vasomotor symptoms associated with menopause, therefore treatment would be off-label. 

**Oxybutynin is not licensed for the treatment of vasomotor symptoms associated with menopause, therefore treatment would be off-label. 

***LFTs were tested and normal prior to therapy, were then done monthly for the first 3 months and no abnormalities noted, and will then be monitored as per SmPC. 

VMS, vasomotor symptoms; HRT, hormone replacement therapy.

 

REFERENCES: 1. VEOZA Summary of Product Characteristics. 2. Data on file Data on File: ref 40499


Adverse events should be reported. For Ireland, Healthcare professionals are asked to report any suspected adverse reactions via: HPRA Pharmacovigilance, Website: www.hpra.ie or Astellas Pharma Co. Ltd. Tel:+353 1 467 1555, E-mail: irishdrugsafety@astellas.com.
 

MAT-IE-VEO-2025-00071 January 2026